BioSpace News Archive

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium.

Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today provided a business update and reported financial results for the first quarter fiscal 2024 ended July 31, 2023.

Madrigal Pharmaceuticals, Inc. announced that it made an inducement grant to Bill Sibold on September 11, 2023 in connection with his appointment as Madrigal’s new President and Chief Executive Officer.

In recent years, scientists have used gene modification technologies to reprogram immune cells into therapeutics that can attack cancers.

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock.

10x Genomics, Inc., a leader in single cell and spatial biology, announced the commercial availability of a new kit to expand the capabilities of its Chromium Single Cell Gene Expression Flex assay to include high-throughput multiomic cellular profiling.

Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV) today announced that net income for the three and nine months ended July 31, 2023 was approximately $0.5 and $1.4 million, respectively, an increase of approximately $0.2 and $0.5 million, when compared to the same periods last year.

CymaBay Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants.

Phanes Therapeutics, Inc. announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company’s Clinical Advisory Board.

Aeglea BioTherapeutics, Inc. (“Aeglea”) (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit.